Cipla Limited
CIPLA
株式のランク
#1810
Cipla Limited, along with its associated entities, operates as a global... Cipla Limited, along with its associated entities, operates as a global pharmaceutical enterprise, specializing in the creation and distribution of a wide array of medicinal products. Its extensive portfolio includes both active pharmaceutical ingredients (APIs) and a diverse range of finished formulations, addressing numerous therapeutic areas such as cardiovascular diseases, metabolic disorders, HIV, respiratory conditions, urology, oncology, pediatric health, infectious diseases, critical care, hepatitis, women's health, ophthalmology, and neuropsychiatry. The company maintains a strong focus on respiratory treatments, offering various inhalers, nasal sprays, injectables, and biosimilars. Cipla has also forged significant partnerships, including a licensing arrangement with Merck & Co., Inc. for the manufacturing and commercialization of the investigational oral antiviral drug Molnupiravir, and a separate license agreement with Eli Lilly and Company for baricitinib, indicated for COVID-19. Furthermore, it collaborates with Dr. Reddy's Laboratories Ltd, Sun Pharmaceutical Industries Limited, Emcure Pharmaceuticals Limited, and Torrent Pharmaceuticals Limited for Molnupiravir's clinical trials. Established in 1935, Cipla's corporate headquarters are located in Mumbai, India.
株価
$14.61
最終同期: 2026-10-19
時価総額
$11.81B
変化（1日）
-0.11%
変化（1年）
-21.65%
国
IN
取引 Cipla Limited (CIPLA)
カテゴリー
Healthcare
Cipla Limited（CIPLA）の株式分割履歴
Cipla Limited株（シンボル：CIPLA）は合計で4回の株式分割を実施しました。
最新の株式分割はApr 24, 2006に行われました。
Oct 18, 1999より前に購入されたCIPLA株は、現在112.5CIPLA株に相当します。
最新の株式分割はApr 24, 2006に行われました。
Oct 18, 1999より前に購入されたCIPLA株は、現在112.5CIPLA株に相当します。
株式分割一覧
| 年 | 株式分割 | 分割比率 | 累積分割比率 |
|---|---|---|---|
| 2006-04-24 | 5:2 | x2.5 | x112.5 |
| 2004-05-11 | 5:1 | x5 | x45 |
| 1999-10-21 | 3:1 | x3 | x9 |
| 1999-10-18 | 3:1 | x3 | x3 |
類似企業または競合他社の株式分割
| 企業 | 株式分割の回数 | 累積分割比率 | 国 |
|---|---|---|---|
| 0 | - |
DE
|
|
| 0 | - |
DE
|
|
| 0 | - |
JP
|
|
| 0 | - |
CH
|
|
| 5 | x119 |
IN
|
